Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: First results from the research on adverse drug events and reports project

Journal of Clinical Oncology

Volumn 21, Issue 20, 2003, Pages 3859-3866

  Ladewski, Lisa A ^b   Belknap, Steven M ^b   Nebeker, Jonathan R ^b   Sartor, Oliver ^b   Lyons, E Allison ^b   Kuzel, Timothy C ^b   Tallman, Martin S ^b   Raisch, Dennis W ^b   Auerbach, Amy R ^b   Schumock, Glen T ^b   Kwaan, Hau C ^b   Bennett, Charles L ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; DRUG APPROVAL; DRUG INDUCED DISEASE; DRUG INFORMATION; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; POSTMARKETING SURVEILLANCE; TIME; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS; DRUG APPROVAL; PRODUCT SURVEILLANCE, POSTMARKETING; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0142023879     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.537     Document Type: Article

References (74)

1. United States General Accounting Office: FDA Drug Review: Postapproval risks, 1976-1985. Washington, DC, US General Accounting Office, publication GAO/PEMD-90-15, April 26, 1990.
2. Hampson JP, Harvey JN: Postmarketing surveillance and black box warnings. JAMA 288:955-956, 2002
3. Brewer T, Colditz GA: Postmarketing surveillance and adverse drug reactions: Current perspectives and future needs. JAMA 281:824-829, 1999
4. Edwards IR, Aronson JK: Adverse drug reactions: Definitions, diagnosis, and management. Lancet 356:1255-1259, 2000
5. Classen DC, Pestotnik SL, Evans RS, et al: Computerized surveillance of adverse drug events in hospital patients. JAMA 266:2847-2851, 1991
6. United States FDA MedWatch. http://www.fda.gov/medwatch/ (accessed 8/21/03)
7. Bennett CL, Raisch DW, Sartor O: Pneumonitis associated with nonsteroidal antiandrogens: Presumptive evidence of a class effect. Ann Intern Med 137:625, 2002
8. Casadevall N, Nataf J, Viron B, et al: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475, 2002
9. Giles FJ, Kantarjian HM, Kornblau SM, et al: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92:406-413, 2001
10. Bicalutamide package insert change for interstitial pneumonitis, 2001. http://www.fda.gov/medwatch/safety/2001/feb01.htm#casode
11. Cyclophosphamide package insert change for Stevens-Johnson syndrome, 2001. http://www.fda.gov/medwatch/SAFETY/2001/jan01.htm#cytoxa
12. Fludarabine package insert change for trilineage hypoplasia or aplasia, 2001. http://www.fda.gov/medwatch/safety/2001/dec01.htm#fludar
13. Gemcitabine package insert change for hemolytic uremic syndrome, 2000. http://www.fda.gov/medwatch/safety/2000/jun00.htm#gemzar
14. Interferon alfa-2a package insert change for severe neuropsychiatric disorders, 2002. http://www.fda.gov/medwatch/SAFETY/2002/roferon_A_PI.pdf
15. Interferon alfa-2b package insert change for severe neuropsychiatric disorders, 2001. http://www.fda.gov/medwatch/safety/2001/oct01.htm#rebetr
16. Pamidronate package insert change for severe renal toxicity, 2002. Available at: http://www.fda.gov/medwatch/SAFETY/2002/jul02.htm#aredia
17. Rituximab package insert change for severe infusion reactions, 1998. http://www.fda.gov/medwatch/safety/1998/safety98.htm#rituxa
18. Tamoxifen package insert change for uterine sarcoma and endometrial adenocarcinoma, 2002. http://www.fda.gov/medwatch/SAFETY/2002/may02.htm#nolvad
19. Trastuzumab package insert change for severe infusion reactions, 2000. http://www.fda.gov/medwatch/safety/2000/herceppi.pdf
20. Vinorelbine package insert change for interstitial pneumonitis, 2000. http://www.fda.gov/medwatch/safety/2000/may00.htm#navelb
21. Capecitabine package insert change for warfarin interaction, 2001. http://www.fda.gov/medwatch/safety/2001/xeloda_changes.PDF
22. Capecitabine package insert change for severe renal insufficiency, 2000. http://www.fda.gov/cder/foi/label/2000/208961bl.pdf
23. Gemtuzumab package insert change for veno-occlusive disease, 2001. http://www.fda.gov/medwatch/SAFETY/2001/may01.htm#mylota
24. Gemtuzumab package insert change for severe infusion reactions, 2001. http://www.fda.gov/medwatch/SAFETY/2001/feb01.htm#mylota
25. Imatinib package insert change for tumor or upper gastrointestinal bleed, 2002. http://www.fda.gov/medwatch/SAFETY/2002/feb02.htm#gleeve
26. Irinotecan package insert change for drug-related fatalities, 2002. http://www.fda.gov/medwatch/SAFETY/2002/camptosar_label_highlighted.pdf
27. Pamidronate initial package insert change for severe renal toxicity, 2001. http://www.fda.gov/medwatch/safety/2001/aug01.htm#aredia
28. Unnikrishnan D, Dutcher JP, Varshneya N, et al: Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 97:1514-1516, 2001
29. Grohskopf LA, Roth VR, Feikin DR, et al: Serratia liquefaciens bloodstream infections from contamination of epoetin alfa at a hemodialysis center. N Engl J Med 344:1491-1497, 2001
30. Fung MC, Storniolo AM, Nguyen B, et al: A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85:2023-2032, 1999
31. Markowitz GS, Appel GB, Fine PL, et al: Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12:1164-1172, 2001
32. Winker U, Jensen M, Manzke O, et al: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab). Blood 94:2217-2224, 1999
33. Bergman L, Beelen ML, Gallee MP, et al: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer: Comprehensive Cancer ALERT Group-Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356:881-887, 2000
34. Dillman RO: Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 18:465-471, 1999
35. Raderer M, Kornek G, Hejna M, et al: Acute pulmonary toxicity associated with high-dose vinorelbine and mitomycin C. Ann Oncol 7:973-975, 1996
36. Sievers EL, Larson RA, Stadtmauer EA, et al: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244-3254, 2001
37. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
38. Sargent DJ, Niedzwiecki D, O'Connell MJ, et al: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345:144-145, 2001
39. Bennett CL, Schumock GT, Desai AA, et al: Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med 113:603-606, 2002
40. Go RS, Call TG: Deep vein thrombosis of the arm after intravenous immunoglobulin infusion: Case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 75:83-85, 2000
41. Arsenic trioxide "Dear Doctor" letter for sudden death or torsades de pointes, 2001. http://www.fda.gov/medwatch/safety/2001/ Trisenox_letter.pdf (accessed 8/21/03)
42. Erythropoietin "Dear Doctor" letter for serratia infection, 2000. http://www.fda.gov/medwatch/safety/2000/cpogen.pdf
43. Immune globulin (human) "Dear Doctor" letter for stroke and other thrombotic episodes, 2002. http://www.fda.gov/medwatch/SAFETY/2002/ baxter_igiv.htm (accessed 8/21/03)
44. Interferon alpha 2a "Dear Doctor" letter for severe neuropsychiatric disorders, 2002. http://www.fda.gov/medwatch/SAFETY/2002/ roferon_deardoc.pdf
45. Oprelvekin "Dear Doctor" letter for papilledema, 2001. http://www.fda.gov/medwatch/safety/2001/neumega.htm
46. Rituximab "Dear Doctor" letter for severe infusion reactions, 1998. http://www.fda.gov/medwatch/safety/1998/rituxa.htm
47. Tamoxifen "Dear Doctor" letter for uterine sarcoma and endometrial adenocarcinoma, 2002. http://www.fda.gov/medwatch/SAFETY/2002/ nolvadex_deardoc.pdf
48. Trastuzumab "Dear Doctor" letter for severe infusion reactions, 2000. http://www.fda.gov/medwatch/safety/2000/hercep1.htm
49. Capecitabine "Dear Doctor" letter for warfarin interaction, 1999. http://www.fda.gov/medwatch/safety/1999/xeloda.htm
50. Capecitabine "Dear Doctor" letter for severe renal insufficiency, 2000. http://www.fda.gov/medwatch/safety/2000/xeloda.pdf
51. Irinotecan "Dear Doctor" letter for drug-related fatalities, 2002. http://www.fda.gov/medwatch/SAFETY/2002/camptosar.htm
52. United States General Accounting Office: FDA Drug Review-Postapproval risks, 1976-85. Washington, DC, US General Accounting Office, publication GAO/PEMD-90-15, April 26, 1990
53. Wood AJ, Stein CM, Woosley R: Making medicines safer: The need for an independent drug safety board. N Engl J Med 339:1851-1854, 1998
54. Martin RM, Kapoor KV, Wilton LV, et al: Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice. BMJ 317:119-120, 1998
55. Mann RD: Prescription event monitoring: Recent progress and future horizons. Br J Clin Pharm 46:195-201, 1998
56. Khong TK, Singer DRJ: Adverse drug reactions: Current issues and strategies for prevention and management. Expert Opin Pharmacother 3:1289-1300, 2002
57. Lasser KE, Allen PD, Woolhandler SJ, et al: Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215-2220, 2002
58. Kolesar JM, Johnson CL, Freeberg BL, et al: Warfarin-5-FU interaction: A consecutive cast series. Pharmacotherapy 19:1445-1449, 1999
59. Baser RL, O'Flaherty E, Green M, et al: Development of pancytopenia with neutralizing antibodies after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 99:2599-2602, 2002
60. Li J, Yang C, Xia Y, et al: Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241-3248, 2001
61. Temple RJ, Himmel MH: Safety of newly approved drugs: Implications for prescribing. JAMA 287:2273-2275, 2002
62. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al: Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases. Ann Intern Med 128:541-544, 1998
63. Aransep [darbepeotin alfa; package insert], Thousand Oaks, CA: Amgen Inc, 2001, http://www.fda.gov/cber/label/darbamg071902LB2.pdf
64. Nancy Lee, Parm D (personal communication, August 25, 2003)
65. Friedman MA, Woodcock J, Lumpkin MM, et al: The safety of newly approved medicines: Do recent market removals mean there is a problem? JAMA 28:1728-1734, 1999
66. Fast track, priority, and accelerated approval: Oncology tools. Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services, http://www.accessdata.fda.gov/scripts/cder/onctools/ Accel.cfm
67. Accelerated approval of new drugs for serious or life-threatening illnesses. 21 Subpart H, Code of Federal Regulations, 314.510, 1992
68. Accelerated approval of new drugs for serious or life-threatening illnesses. 21 Subpart H, Code of Federal Regulations, 314.510, 1992
69. Clinton W, Gore A: Reinventing the regulation of cancer drugs: National performance review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3936B1_01_C- Attachment%202.pdf
70. Dagher R: Accelerated Approvals in Oncology: A 10-Year Experience. March 12, 2003. Presentation to the Oncologic Drugs Advisory Committee. http://www.fda.gov/ohrms/dockets/ac/03/slides/3936sl.htm
71. Pazdur R: Accelerated Approvals in Oncology. March 12, 2003. Presentation to the Oncologic Drugs Advisory Committee. http://www.fda.gov/ohrms/dockets/ac/ 03/slides/3936sl.htm
72. Woolsey R: Drug labeling revisions: Guaranteed to fail. JAMA 284:3047-3049, 2000
73. Brinker A, Staffa J: Concurrent use of selected agents with moxifloxacin: An examination of labeling compliance within 1 year of marketing. Arch Intern Med 162:2011-2012, 2002
74. Understanding the approval process for new cancer drugs: Q&A-Off-label drugs. http://www.nci.nih.gov/clinicaltrials/understanding/ approval-process-for-cancer-drugs/page5